DK0495896T3 - Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel - Google Patents
Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middelInfo
- Publication number
- DK0495896T3 DK0495896T3 DK90915992.3T DK90915992T DK0495896T3 DK 0495896 T3 DK0495896 T3 DK 0495896T3 DK 90915992 T DK90915992 T DK 90915992T DK 0495896 T3 DK0495896 T3 DK 0495896T3
- Authority
- DK
- Denmark
- Prior art keywords
- hiv
- infections
- protection against
- vaccine
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000000032 diagnostic agent Substances 0.000 title abstract 2
- 239000002955 immunomodulating agent Substances 0.000 title abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 208000031886 HIV Infections Diseases 0.000 abstract 6
- 241000713340 Human immunodeficiency virus 2 Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3934366A DE3934366A1 (de) | 1989-10-14 | 1989-10-14 | Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0495896T3 true DK0495896T3 (da) | 1994-10-10 |
Family
ID=6391493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK90915992.3T DK0495896T3 (da) | 1989-10-14 | 1990-10-12 | Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel |
Country Status (8)
Country | Link |
---|---|
US (1) | US5861243A (da) |
EP (1) | EP0495896B1 (da) |
JP (1) | JP3152433B2 (da) |
AT (1) | ATE106748T1 (da) |
DE (2) | DE3934366A1 (da) |
DK (1) | DK0495896T3 (da) |
ES (1) | ES2055922T3 (da) |
WO (1) | WO1991005567A1 (da) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL98845A0 (en) * | 1990-07-19 | 1992-07-15 | Merck & Co Inc | Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them |
US5274122A (en) * | 1992-10-15 | 1993-12-28 | Merck & Co., Inc. | Acidic derivatives of homocysteine thiolactone |
AU715731B2 (en) * | 1994-10-20 | 2000-02-10 | Institut Pasteur | Nucleotide sequences of HIV-1 group (or subtype) O retrovirus antigens |
US6124262A (en) * | 1995-03-17 | 2000-09-26 | The Regents Of The University Of California | Compositions and methods for reducing adhesiveness of defective red blood cells |
US6426412B1 (en) * | 1995-12-20 | 2002-07-30 | Subsidiary No. 3, Inc. | Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements |
US7144699B2 (en) * | 1997-03-20 | 2006-12-05 | Affymetrix, Inc. | Iterative resequencing |
US5891994A (en) * | 1997-07-11 | 1999-04-06 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
WO2000029561A2 (en) | 1999-03-29 | 2000-05-25 | Statens Serum Institut | Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
ATE516046T1 (de) | 1999-05-13 | 2011-07-15 | Wyeth Corp | Adjuvans kombinationsformulierungen |
DE60043856D1 (de) * | 1999-12-23 | 2010-04-01 | Medical Res Council | Verbesserungen in oder in bezug auf immunantworten gegen hiv |
US6399067B1 (en) * | 2000-04-28 | 2002-06-04 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
SK5482003A3 (en) * | 2000-11-10 | 2004-03-02 | Wyeth Corp | Adjuvant combination formulations |
US8076060B2 (en) * | 2003-08-04 | 2011-12-13 | Emil William Chynn | Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma |
JP2008535783A (ja) | 2005-02-15 | 2008-09-04 | サイモン・エル・エル・シー | Hiv−1の増殖を弱めるための方法および組成物 |
US20100275278A1 (en) * | 2006-02-03 | 2010-10-28 | Karp Nelson M | Animal model for hiv induced disease |
KR101701198B1 (ko) | 2008-06-19 | 2017-02-01 | 배리에이션 바이오테크놀로지스 아이엔씨. | 인플루엔자를 치료하기 위한 조성물 및 방법 |
WO2011005772A1 (en) | 2009-07-06 | 2011-01-13 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
AU2010270722B2 (en) | 2009-07-06 | 2015-06-04 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
US9610248B2 (en) | 2010-07-06 | 2017-04-04 | Variation Biotechnologies, Inc. | Compositions and methods for treating influenza |
CN103501811B (zh) | 2011-01-13 | 2016-03-30 | 变异生物技术公司 | 用于治疗病毒感染的组合物和方法 |
WO2012170765A2 (en) | 2011-06-10 | 2012-12-13 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CN104302323A (zh) | 2012-01-12 | 2015-01-21 | 变异生物技术公司 | 用于治疗病毒感染的组合物和方法 |
US20150079077A1 (en) | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
CN115124628B (zh) * | 2021-03-27 | 2023-03-31 | 中国科学院昆明植物研究所 | 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU608294B2 (en) * | 1987-01-16 | 1991-03-28 | Institut Pasteur | Peptides having immunological properties 2-hiv-2 |
ATE141946T1 (de) * | 1988-06-14 | 1996-09-15 | Qiagen Gmbh | Hiv-2-virusvarianten |
-
1989
- 1989-10-14 DE DE3934366A patent/DE3934366A1/de active Granted
-
1990
- 1990-10-12 JP JP51473190A patent/JP3152433B2/ja not_active Expired - Fee Related
- 1990-10-12 WO PCT/EP1990/001729 patent/WO1991005567A1/de not_active Application Discontinuation
- 1990-10-12 DK DK90915992.3T patent/DK0495896T3/da active
- 1990-10-12 DE DE59006080T patent/DE59006080D1/de not_active Revoked
- 1990-10-12 AT AT90915992T patent/ATE106748T1/de not_active IP Right Cessation
- 1990-10-12 EP EP90915992A patent/EP0495896B1/de not_active Revoked
- 1990-10-12 ES ES90915992T patent/ES2055922T3/es not_active Expired - Lifetime
-
1997
- 1997-11-12 US US08/968,689 patent/US5861243A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH05505389A (ja) | 1993-08-12 |
EP0495896B1 (de) | 1994-06-08 |
DE3934366C2 (da) | 1991-11-07 |
ATE106748T1 (de) | 1994-06-15 |
DE59006080D1 (de) | 1994-07-14 |
WO1991005567A1 (de) | 1991-05-02 |
ES2055922T3 (es) | 1994-09-01 |
US5861243A (en) | 1999-01-19 |
DE3934366A1 (de) | 1991-04-18 |
EP0495896A1 (de) | 1992-07-29 |
JP3152433B2 (ja) | 2001-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0495896T3 (da) | Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel | |
ATE135747T1 (de) | Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids | |
FI102382B1 (fi) | Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten | |
DE69630457D1 (de) | Verbindungen zur immunotherapie und diagnose von tuberkulose | |
ES2054657T3 (es) | Nuevos oligosacaridos y su metodo de preparacion. | |
HUP0302965A2 (hu) | Vakcina | |
EP0232798A3 (en) | Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same | |
NO912825D0 (no) | Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper. | |
GR3022248T3 (en) | Oligonucleotide sequences for amplification of type HIV-2 and SIV retroviruses genomes and their application to in-vitro diagnostic of infections caused by these viruses | |
HUP0303431A2 (hu) | PRRS vírus élő legyengített törzsei | |
ES426215A1 (es) | Procedimiento para preparar una vacuna de adenovirus bovi- nos vivos. | |
EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
PT85093A (fr) | Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a. | |
NO890565D0 (no) | Forhindring og behandling av retroviral sykdom. | |
DK612889A (da) | Enzym og fremgangsmaade til fremstilling deraf | |
CA2350127A1 (en) | Avipox vector coding an hiv antigen and a cytokine | |
ATE143373T1 (de) | Proteine, vakzine und nucleinsäuren | |
TH6220EX (th) | ไวรัสแอนทิเจนวิธีการเตรียมและการใช้ในการวินิจฉัยและในการรักษา(วัคซีน) | |
FR2792639B1 (fr) | Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida | |
TH6220A (th) | ไวรัสแอนทิเจนวิธีการเตรียมและการใช้ในการวินิจฉัยและในการรักษา(วัคซีน) | |
FI945110A (fi) | Tippuribakteerien rokotteiden valmistusmenetelmä | |
TH9629EX (th) | โพรเทเอส, รีเวอร์ส แทรนส์คริพเทส และเอนโดนิวคลี เอสของ ของเรโทรไวรัส และวิธีการสำหรับผลิตเอนไซม์เหล่า นี้ | |
TH23870EX (th) | วัคซีนและวิธีสำหรับการเตรียม | |
TH23870A (th) | วัคซีนและวิธีสำหรับการเตรียม |